PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

24 Apr 2015 17:30

RNS Number : 3240L
AstraZeneca PLC
24 April 2015
 



ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2015

 

Results of Annual General Meeting held on 24 April 2015

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014

 

877,576,463

99.67

2,921,581

0.33

880,498,044

69.68%

10,675,935

2

To confirm dividends

 

886,527,613

99.66

2,986,602

0.34

889,514,215

70.40%

1,659,763

3

To re-appoint KPMG LLP, London as Auditor

 

876,751,815

98.61

12,397,571

1.39

889,149,386

70.37%

2,024,593

4

To authorise the Directors to agree the remuneration of the Auditor

 

887,495,062

99.82

1,629,520

0.18

889,124,582

70.37%

2,049,398

5a

To re-elect Leif Johansson as a Director

 

851,461,560

95.76

37,705,142

4.24

889,166,702

70.37%

2,007,277

5b

To re-elect Pascal Soriot as a Director

 

888,590,119

99.95

426,241

0.05

889,016,360

70.36%

2,157,620

5c

To re-elect Marc Dunoyer as a Director

 

885,602,969

99.62

3,374,856

0.38

888,977,825

70.36%

2,196,155

5d

To elect Cori Bargmann as a Director

 

888,638,513

99.96

351,446

0.04

888,989,959

70.36%

2,184,021

5e

To re-elect Geneviève Berger as a Director

 

888,552,754

99.95

465,106

0.05

889,017,860

70.36%

2,156,120

5f

To re-elect Bruce Burlington as a Director

 

880,639,560

99.88

1,091,107

0.12

881,730,667

69.78%

9,443,312

5g

To re-elect Ann Cairns as a Director

 

888,587,093

99.95

465,731

0.05

889,052,824

70.36%

2,121,156

5h

To re-elect Graham Chipchase as a Director

 

876,994,757

99.46

4,732,631

0.54

881,727,388

69.78%

9,445,684

5i

To re-elect Jean-Philippe Courtois as a Director

 

880,585,784

99.87

1,137,760

0.13

881,723,544

69.78%

9,450,753

5j

To re-elect Rudy Markham as a Director

 

855,335,488

99.27

6,300,712

0.73

861,636,200

68.19%

29,537,348

5k

To re-elect Shriti Vadera as a Director

 

888,387,120

99.93

582,556

0.07

888,969,676

70.36%

2,204,192

5l

To re-elect Marcus Wallenberg as a Director

 

846,091,821

98.19

15,599,701

1.81

861,691,522

68.20%

29,482,025

6

To approve the Annual Report on Remuneration for the year ended 31 December 2014

739,049,685

84.11

139,601,566

15.89

878,651,251

69.54%

12,522,725

7

To authorise limited EU political donations

 

859,081,444

97.36

23,307,997

2.64

882,389,441

69.83%

8,784,535

8

To authorise the Directors to allot shares

 

808,454,239

91.14

78,551,101

8.86

887,005,340

70.20%

4,168,208

9

To authorise the Directors to disapply pre-emption rights

 

875,263,416

98.61

12,347,679

1.39

887,611,095

70.25%

3,562,455

10

To authorise the Company to purchase its own shares

 

876,130,644

98.54

13,023,264

1.46

889,153,908

70.37%

2,019,960

11

To reduce the notice period for general meetings

 

778,280,838

87.53

110,881,255

12.47

889,162,093

70.37%

2,011,885

12

To adopt new Articles of Association

886,456,629

99.90

900,552

0.10

887,357,181

70.23%

3,813,971

 

 

 

Issued capital

As at 22 April 2015, the number of issued shares of the Company was 1,263,544,938, ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

24 April 2015

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUQCCUPAGAC
Date   Source Headline
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.